Veeva Sys Inc Stock Price, News & Analysis

Veeva Systems (NYSE: VEEV) has announced its upcoming virtual Investor Day scheduled for Thursday, November 7, 2024. The event will run from 1:30 p.m. to 3:30 p.m. PT (4:30 p.m. to 6:30 p.m. ET). Interested parties can attend the event by registering online through Veeva's investor relations website or via a direct link provided.

The company will broadcast the presentations live on its investor relations website, ir.veeva.com. For those unable to attend the live event, an archived webcast will be made available on the same platform after the event concludes.

This virtual Investor Day provides an opportunity for stakeholders to gain insights into Veeva Systems' performance, strategies, and future outlook directly from the company's leadership team.

Veeva Systems (NYSE: VEEV) announced that 18 of the top 20 medtech companies are using Veeva Development Cloud and Veeva Commercial Cloud applications to streamline processes across the total medtech product lifecycle. Over 125 customers are leveraging Veeva MedTech's expertise and technology from ideation to commercialization.

Veeva MedTech offers end-to-end product lifecycle management with Vault Clinical, Vault RIM, Vault Quality, and Vault Commercial applications. These solutions provide real-time insights, automate processes, and maintain inspection readiness, reducing manual work and improving cross-team collaboration.

The upcoming Veeva MedTech EU Summit in Amsterdam (Nov. 5-7) will feature industry leaders sharing insights and best practices.

Veeva Systems (NYSE: VEEV) has announced an expansion of Veeva Vault QMS, adding new capabilities for managing medtech field actions and product recalls. These features aim to improve oversight, timeliness, and accuracy throughout the field action process, from issue identification to closure.

The new capabilities are fully integrated into Vault QMS, connecting seamlessly with related quality processes such as complaint handling, quality risk management, CAPA, and change control. This integration reduces manual transcription needs and enhances efficiency.

Matt Roberts, senior director of quality systems at Teleflex, praised the collaboration with Veeva MedTech, stating that the new field actions capabilities will help streamline processes and better serve customers. Vishaka Rajaram, senior director of quality strategy at Veeva MedTech, emphasized the complex nature of field actions management and how Veeva Vault QMS addresses industry needs.

Veeva Systems (NYSE: VEEV) has announced a major release of Veeva Site Connect, enhancing clinical trial execution for sites and sponsors. The update includes new capabilities and a streamlined site-centric experience to simplify sponsor-site collaboration. Key features include:

1. Expanded functionality beyond document exchange and safety distribution
2. Optimized site user interface standardized across all trials
3. Open accessibility for all sites globally
4. Fixed-price implementation with 2-4 month setup

Seven of the top 20 biopharmas have already adopted Veeva Site Connect, aiming to reduce time and effort in site start-up, study conduct, and closeout. The platform is part of Veeva Clinical Platform, supporting patients, sites, and sponsors in streamlining clinical trials.

Veeva Systems (NYSE: VEEV) has announced its participation in the upcoming Citi 2024 Global TMT Conference in New York. Paul Shawah, EVP Strategy at Veeva, is scheduled to present on Wednesday, September 4, 2024, at 3:00 p.m. Eastern Time.

The presentation will be webcast live and archived for later viewing. Interested parties can access the webcast through Veeva's investor relations website at https://ir.veeva.com. This event provides an opportunity for investors and analysts to gain insights into Veeva's strategies and market position in the technology, media, and telecommunications sectors.

Veeva Systems (NYSE: VEEV) reported strong fiscal 2025 Q2 results, with total revenues of $676.2M, up 15% year-over-year, and subscription services revenues of $561.3M, up 19% year-over-year. The company's operating income increased 60% to $166.5M, while non-GAAP operating income rose 32% to $279.8M. Net income grew 53% to $171.0M, with non-GAAP net income up 35% to $267.3M.

Veeva highlighted key product advances, including the release of Vault CRM Service Center and enhancements to Veeva Site Connect. The company also provided guidance for Q3 FY2025, projecting total revenues between $682M and $685M, and updated its full-year FY2025 guidance to total revenues between $2,704M and $2,710M.

Veeva Systems (NYSE: VEEV) has unveiled Veeva Vault CRM Service Center, a new addition to its Vault CRM Suite. This tool is designed for inside sales, contact center, and hybrid representatives in the life sciences industry. It offers case management, video calls, telephony integration, and industry-specific features like consent and sampling. The Service Center integrates with Microsoft 365, enhancing productivity through collaboration in Teams and OneNote.

The Vault CRM Suite aims to unify sales, marketing, medical, and service teams, eliminating silos and providing a customer-centric experience. It includes Vault CRM for sales and Campaign Manager for marketing, all built on the Vault Platform. The suite offers compliant omnichannel engagement, events management, and AI-powered insights. Over 15 companies are already using Vault CRM, with migrations for smaller customers starting in Q4 2024 and larger ones in early 2025.

Veeva Systems (NYSE: VEEV) announced increasing momentum for Veeva Vault LIMS, a cloud solution that simplifies quality control (QC) processes. Vault LIMS is unified with Veeva Vault Quality, enabling customers to share data across quality applications for more informed batch release decisions. The solution aims to bring together quality assurance (QA) and QC to improve efficiency, compliance, and right-first-time execution.

Forge Biologics' senior director of QC analytical testing, Andrew Laughhunn, highlighted the potential for streamlined method execution and minimized documentation errors. Vault LIMS offers a complete QC management and test execution solution that can be deployed quickly, reducing reliance on IT teams and lowering total cost of ownership. The solution is suitable for both established organizations and fast-growing biotechs.

Veeva Systems (NYSE: VEEV) has announced the upcoming 2024 Veeva R&D and Quality Summit in Boston on Sept. 9-10. This event, one of the largest in life sciences, will bring together over 2,000 industry professionals to discuss how connected systems across clinical, regulatory, safety, and quality can advance drug development.

Keynote speakers from leading companies like AbbVie, Astellas, Eikon Therapeutics, Merck & Co., Moderna, and Roche will share insights on various topics. These include pharmacovigilance transformation, clinical process optimization, scalable development foundations, quality control modernization, and AI-powered translation for faster submissions.

Veeva CEO Peter Gassner will headline the opening keynote, focusing on how connected data and systems can streamline drug development and accelerate product time to market. The summit will feature over 100 sessions, providing ample networking and learning opportunities for attendees.